Inhaled Chelating Agent for Lung Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung inflammation, such as cystic fibrosis, are inadequate due to transient effects and significant side effects, and there is a need for alternative methods to effectively manage inflammation in the lungs.
Innovation Solution
Administering a high concentration of an inhaled chelating agent, specifically calcium EDTA, to reduce inflammation by chelating zinc and iron, thereby inhibiting matrix metalloproteinases and reducing reactive oxygen species production, which helps in decreasing bacterial load and biofilm formation in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral or inhaled steroids and non-steroidal medications are used to treat lung inflammation, then inflammation is reduced, but the effects are transient and require continuous treatment with significant side effects
Solution Approach 1:
The patent changes the mechanism of action from suppressing inflammation directly (steroids) to removing iron from the lung environment (chelation). Iron removal prevents the formation of reactive oxygen species that drive inflammation, providing a more durable effect that resolves the contradiction between inflammation reduction and duration of action.
2Reliability
If oral or inhaled steroids and non-steroidal medications are used to treat lung inflammation, then inflammation is reduced, but there are significant side effects
Solution Approach 1:
The patent extracts iron from the lung environment through inhaled chelating agents, removing the fundamental cause of inflammation rather than suppressing it. This extraction approach eliminates the need for continuous steroid therapy and its associated harmful side effects, while directly addressing the root problem of iron-driven inflammation.
3Reliability
If high concentration of inhaled chelating agent is administered, then inflammation is reduced and lung function is improved, but the complexity of administration increases
Solution Approach 1:
The patent uses a nebulizer device to deliver the chelating agent as an aerosol, utilizing pneumatic principles to generate fine particles that reach the lung parenchyma. This pneumatic delivery system simplifies administration compared to oral formulations, as it provides direct lung targeting with ease of use, resolving the contradiction between effective inflammation reduction and administration complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively increases forced expiratory volume (FEV) and decreases matrix metalloproteinase activity and hydroxyl radical production, providing sustained inflammation reduction and improved lung function without systemic side effects.
Implementation Method 1
Administering a high concentration of an inhaled chelating agent, specifically calcium EDTA, to reduce inflammation by chelating zinc and iron
Implementation Method 2
chelating zinc and iron, thereby inhibiting matrix metalloproteinases and reducing reactive oxygen species production, which helps in decreasing bacterial load and biofilm formation
Data Source
AI summary
A method of treating or preventing inflammation in the lung by administering a high concentration of an inhaled chelating agent.